^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

CD20 (Membrane Spanning 4-Domains A1)

i
Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
2d
Enrollment open
|
ABL1 (ABL proto-oncogene 1) • CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive • CD20 negative
|
Rituxan (rituximab) • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
3d
Fluid Overload-Associated Large B-Cell Lymphoma Presenting as Isolated Pleural Effusion. (PubMed, Hematol Rep)
Ultimately, the patient was diagnosed with fluid overload-associated large B-cell lymphoma and treated with rituximab, cyclophosphamide, vincristine sulfate, and prednisone, but passed away three months after diagnosis. It may be mistaken for other conditions such as primary effusion lymphoma or other diffuse large B-cell lymphomas. The presence of a Human Herpesvirus-8-negative effusion-based lymphoma in an elderly immunocompetent patient without nodal or tissue involvement should prompt consideration of fluid overload-associated large B-cell lymphoma.
Journal • Pleural effusion
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • WT1 (WT1 Transcription Factor) • PAX5 (Paired Box 5) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NKX2-1 (NK2 Homeobox 1) • SDC1 (Syndecan 1) • CD68 (CD68 Molecule) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4)
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • vincristine • prednisone
3d
Mantle Cell Lymphoma with Persistent Massive Pleural Effusions Requiring Invasive Mechanical Ventilation and Bilateral Continuous Thoracic Drainage. (PubMed, Reports (MDPI))
Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was commenced under mechanical ventilation. A thorough diagnostic workup followed by prompt initiation of immunochemotherapy can arrest pleural output, enable extubation, and be lifesaving. Clinicians should recognize that MCL rarely presents with persistent massive pleural effusions.
Journal • Pleural effusion
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
4d
ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov)
P3, N=635, Active, not recruiting, Acerta Pharma BV | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2027
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14)
|
Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)
5d
ARGUS project: A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps (clinicaltrials.gov)
P=N/A, N=400, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD20 (Membrane Spanning 4-Domains A1)
7d
Diffuse Large B-Cell Lymphoma Presenting With Isolated Splenomegaly in a 42-Year-Old Female: A Rare Incidence of Primary Splenic Involvement. (PubMed, Cureus)
She received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, which she tolerated well. Post-treatment PET-CT revealed a complete metabolic response, and subsequent follow-up has shown no evidence of disease recurrence. This report illustrates that isolated splenomegaly can be the first and only manifestation of DLBCL and emphasizes the role of splenectomy as both a diagnostic and therapeutic option in carefully selected patients.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IRF4 (Interferon regulatory factor 4)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
7d
Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer. (PubMed, Lung Cancer)
Clinical parameters remain the dominant predictors of outcome in NSCLC, with immune cell densities providing only limited prognostic value for clinical stratification. The openly available code and datasets present a unique resource for method development or focused analysis.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
8d
Concurrent Development of B-Cell Lymphoblastic Lymphoma and Histiocytic Sarcoma in a C57BL/6 Laboratory Mouse: A Case Report. (PubMed, Vet Med Sci)
While single cases of similar composite neoplasms have been reported in humans, this is the first documented case in a laboratory mouse. These findings expand the known spectrum of spontaneous hematopoietic tumours in aged mice and highlight the importance of comprehensive histopathological and immunophenotypic evaluation in diagnosing atypical lesions.
Preclinical • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • PAX5 (Paired Box 5) • PCNA (Proliferating cell nuclear antigen)
|
CD20 positive
9d
Differential Expression of CD79B, CD19, and PD-L1 in de Novo and Transformed CD20-Negative Large B-Cell Lymphomas. (PubMed, Hematol Oncol)
CD20-negative large B-cell lymphomas exhibit aggressive behavior and are ineligible for rituximab-containing therapy...In conclusion, CD79B and CD19 were variably expressed in CD20-negative large B-cell lymphomas, but lower in de novo DLBCL, and especially in plasmablastic lymphoma. Programmed cell death protein 1/programmed death-ligand one inhibitors may represent a treatment option.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1) • CD79B (CD79b Molecule)
|
CD20 positive • CD20 negative
|
Rituxan (rituximab)
9d
Clinical and pathological characteristics and prognostic analysis of colorectal cancer associated with breast cancer susceptibility gene mutations (PubMed, Zhonghua Zhong Liu Za Zhi)
Multivariate Cox regression analysis identified clinical stage as an independent predictor of overall survival, with patients at stages Ⅲ-Ⅳ exhibiting poorer prognosis (HR=5.359, 95% CI: 1.124-25.546). BRCA-mutated colorectal tumors exhibit lower invasiveness, higher TMB-H rates, and abundant immune cell infiltration in the tumor microenvironment, suggesting that patients with BRCA-mutated colorectal cancer are more likely to benefit from immunotherapy.
Journal • BRCA Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
|
BRCA2 mutation • BRCA1 mutation • TMB-H • BRCA wild-type • BRCA mutation
9d
Invasive carcinoma of no special type with medullary pattern in the canine mammary gland: histopathological and immunohistochemical characterization. (PubMed, J Comp Pathol)
This case reinforces the importance of recognizing MC in dogs as it shares several histopathological and immunohistochemical features with its human counterpart. Further studies with larger cohorts are needed to elucidate the prognostic significance of this rare tumour subtype in dogs.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD20 (Membrane Spanning 4-Domains A1)
9d
Enrollment closed • Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)